Cargando…

Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports

BACKGROUND: Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance in IgAN, although this has never been attempted before. We explored whether FMT c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jin, Bai, Ming, Yang, Xiaoxia, Wang, Yan, Li, Rong, Sun, Shiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901287/
https://www.ncbi.nlm.nih.gov/pubmed/34134605
http://dx.doi.org/10.1080/0886022X.2021.1936038
_version_ 1784664330607788032
author Zhao, Jin
Bai, Ming
Yang, Xiaoxia
Wang, Yan
Li, Rong
Sun, Shiren
author_facet Zhao, Jin
Bai, Ming
Yang, Xiaoxia
Wang, Yan
Li, Rong
Sun, Shiren
author_sort Zhao, Jin
collection PubMed
description BACKGROUND: Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance in IgAN, although this has never been attempted before. We explored whether FMT could be efficacious in treating IgAN in two patients with refractory IgAN. CASE PRESENTATION: Two Chinese female patients with IgAN failed to achieve clinical remission after receiving several rounds of immunosuppressive therapy and suffered from unbearable adverse effects due to immunosuppressants. Both patients received intensive fresh FMT conducted through transendoscopic enteral tubing (TET) regularly for 6–7 months, and were followed up for a further 6 months. Partial clinical remission was achieved in both patients, evidenced by a decrease in the 24-h urinary protein (24-hUP) to less than half of baseline during FMT treatment or follow-up, along with increased serum albumin (sAlb) and stable kidney function. The gut microbiota of both patients was distorted with lower biodiversity and altered composition, which was reversed following FMT. Phylum Proteobacteria decreased while genus Prevotella increased during and after FMT. The intensive fresh FMT was well-tolerated, and no severe adverse events occurred. CONCLUSIONS: Preliminary evidence of the safety and efficacy of FMT for treating refractory IgAN may provide a new direction by which to decipher the pathogenesis of IgAN.
format Online
Article
Text
id pubmed-8901287
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-89012872022-03-08 Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports Zhao, Jin Bai, Ming Yang, Xiaoxia Wang, Yan Li, Rong Sun, Shiren Ren Fail Brief Report BACKGROUND: Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance in IgAN, although this has never been attempted before. We explored whether FMT could be efficacious in treating IgAN in two patients with refractory IgAN. CASE PRESENTATION: Two Chinese female patients with IgAN failed to achieve clinical remission after receiving several rounds of immunosuppressive therapy and suffered from unbearable adverse effects due to immunosuppressants. Both patients received intensive fresh FMT conducted through transendoscopic enteral tubing (TET) regularly for 6–7 months, and were followed up for a further 6 months. Partial clinical remission was achieved in both patients, evidenced by a decrease in the 24-h urinary protein (24-hUP) to less than half of baseline during FMT treatment or follow-up, along with increased serum albumin (sAlb) and stable kidney function. The gut microbiota of both patients was distorted with lower biodiversity and altered composition, which was reversed following FMT. Phylum Proteobacteria decreased while genus Prevotella increased during and after FMT. The intensive fresh FMT was well-tolerated, and no severe adverse events occurred. CONCLUSIONS: Preliminary evidence of the safety and efficacy of FMT for treating refractory IgAN may provide a new direction by which to decipher the pathogenesis of IgAN. Taylor & Francis 2021-06-16 /pmc/articles/PMC8901287/ /pubmed/34134605 http://dx.doi.org/10.1080/0886022X.2021.1936038 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Zhao, Jin
Bai, Ming
Yang, Xiaoxia
Wang, Yan
Li, Rong
Sun, Shiren
Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title_full Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title_fullStr Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title_full_unstemmed Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title_short Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports
title_sort alleviation of refractory iga nephropathy by intensive fecal microbiota transplantation: the first case reports
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901287/
https://www.ncbi.nlm.nih.gov/pubmed/34134605
http://dx.doi.org/10.1080/0886022X.2021.1936038
work_keys_str_mv AT zhaojin alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports
AT baiming alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports
AT yangxiaoxia alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports
AT wangyan alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports
AT lirong alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports
AT sunshiren alleviationofrefractoryiganephropathybyintensivefecalmicrobiotatransplantationthefirstcasereports